Related Experiment Video
Updated: May 14, 2026
06:13
Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Zinc supplementation in pre-diabetes: study protocol for a randomized controlled trial.
Priyanga Ranasinghe1, Ranil Jayawardena, A S A D Pigera
1Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka. priyanga.ranasinghe@gmail.com
Trials
|February 21, 2013
Summary
Zinc supplementation may improve glycemic control in individuals with pre-diabetes. This 12-month randomized controlled trial will assess zinc
Area of Science:
- Metabolic Health
- Nutritional Science
- Clinical Trials
Background:
- Global rise in diabetes, particularly in South Asia, necessitates early prevention strategies.
- Emerging evidence suggests zinc benefits glycemic and metabolic control in diabetes.
- Pre-diabetes represents a critical window for intervention to prevent type 2 diabetes.
Purpose of the Study:
- To evaluate the effects of zinc supplementation on glycemic control in pre-diabetic adults.
- To assess zinc's impact on other metabolic parameters in pre-diabetes.
- To determine zinc's potential role in preventing diabetes mellitus progression.
Main Methods:
- Randomized, double-blind, placebo-controlled trial over 12 months.
- 200 adults with pre-diabetes stratified and randomized (1:1) into zinc (20 mg/day) or placebo groups.
- Primary outcomes: fasting plasma glucose, HbA1c, lipid profile, serum insulin; Secondary outcomes: blood pressure, anthropometry.
Main Results:
- This section is not available in the provided abstract.
Conclusions:
- Zinc supplementation shows promise for improving metabolic parameters in pre-diabetes.
- Further research is warranted to confirm zinc's efficacy in diabetes prevention.
- This study aims to establish zinc's beneficial effects on disease progression in pre-diabetes.
Related Concept Videos
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...